1. Home
  2. Faculty

Mohammed Milhem, MBBS

Clinical Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation

Current Positions

  • Clinical Professor of Internal Medicine-Hematology, Oncology, and Blood & Marrow Transplantation
  • Holden Chair of Experimental Therapeutics
  • Associate Director of Clinical Research, Holden Comprehensive Cancer Center
  • Director, Melanoma Program, Holden Comprehensive Cancer Center

Education

  • MBBS, Jordan University, Amman, Jordan
  • Residency, Internal Medicine, University of Illinois at Chicago, Chicago, Illinois
  • Fellowship, Hematology/Oncology, University of Illinois at Chicago, Chicago, Illinois
  • Fellowship, Bone Marrow Transplant, University of Illinois at Chicago, Chicago, Illinois

Licenses & Certifications

  • Certification, American Board of Internal Medicine
  • Certification, American Board of Internal Medicine, Hematology
  • Certification, American Board of Internal Medicine, Oncology

Selected Publications

  • Holcombe RF, Verschraegen CF, Chapman AE, Gaffney D, Goldberg RM, Mesa RA, Milhem MM, Mims M, Mitchell EP, Mulkerin D, Vijayakumar S.  Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care. J Natl Compr Canc Netw. 2021 Feb 2;19(2):122-125. PMID: 33545684
  • Zafar FS, Richey P, Okereke U, Milhem MM, Abid R, Powers JG. Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature.  Melanoma Res. 2021 Feb 1;31(1):98-100. PMID: 33323722
  • Javed A, Milhem MM.  Role of Natural Killer Cells in Uveal Melanoma. Cancers (Basel). 2020 Dec 9;12(12):3694. PMID: 33317028
  • Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS.  A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 Mar 15;127(6):894-904. PMID: 33231866
  • Swami U, Chennamadhavuni A, Borcherding N, Bossler AD, Mott SL, Garje R, Zakharia Y, Milhem MM. Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies. Antibiotics (Basel). 2020 Oct 27;9(11):740. PMID: 33120998
  • Hirbe AC, Eulo V, Moon CI, Luo J, Myles S, Seetharam M, Toeniskoetter J, Kershner T, Haarberg S, Agulnik M, Monga V, Milhem MM, Parkes A, Robinson S, Okuno S, Attia S, Van Tine BA. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Eur J Cancer. 2020 Sep;137:1-9. PMID: 32712457
  • Callaghan CM, Seyedin SN, Mohiuddin IH, Hawkes KL, Petronek MS, Anderson CM, Buatti JM, Milhem MM, Monga V, Allen BG.  The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma.  Radiat Res. 2020 Aug 1;194(2):124-132. PMID: 32845986
  • Callaghan CM, Hasibuzzaman MM, Rodman SN, Goetz JE, Mapuskar KA, Petronek MS, Steinbach EJ, Miller BJ, Pulliam CF, Coleman MC, Monga VV, Milhem MM, Spitz DR, Allen BG. Neoadjuvant Radiotherapy-Related Wound Morbidity in Soft Tissue Sarcoma: Perspectives for Radioprotective Agents. Cancers (Basel)2020 Aug 12;12(8):E2258. PMID: 32806601
  • Monga V, Skubitz KM, Maliske S, Mott SL, Dietz H, Hirbe AC, Van Tine BA, Oppelt P, Okuno S, Robinson S, O'Connor M, Seetharam M, Attia S, Charlson J, Agulnik M, Milhem MM.  A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas.  Cancers (Basel).PMID: 32664595
  • Monga V, Mani H, Hirbe A, Milhem MM. Non-Conventional Treatments for Conventional Chondrosarcoma. Cancers (Basel) 2020 Jul 19;12(7):E1962. PMID: 32707689